Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole IV to Oral Switch in Immunocompromised Children
NCT01383993Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2011
- Primary completion
- May 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of voriconazole in fungal infection (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) at Day 14, Maximum Observed Plasma Concentration at Steady State (Cmax,ss) at Day 14 and 4 more. Started Sep 2011; status: completed.
02
Drugs
voriconazole
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT01383993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01383993.